Recent progress in the understanding and treatment of transthyretin amyloidosis

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 3, 2014, Pages 225-233

  Sekijima, Y ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

amyloidosis; antisense oligonucleotide; diflunisal; familial amyloid polyneuropathy; senile systemic amyloidosis; siRNA; tafamidis; transthyretin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DIFLUNISAL; PREALBUMIN; SMALL INTERFERING RNA; TAFAMIDIS; TETRAMER; UNCLASSIFIED DRUG; VYNDAQUEL; BENZOXAZOLE DERIVATIVE;

AMYLOIDOSIS; ANTISENSE THERAPY; CELL PROTECTION; DISEASE SEVERITY; HUMAN; LIVER TRANSPLANTATION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; TRANSTHYRETIN AMYLOIDOSIS; AMYLOID NEUROPATHIES, FAMILIAL; GENE THERAPY; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES;

AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; DIFLUNISAL; GENETIC THERAPY; HUMANS; LIVER TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PREALBUMIN; RNA, SMALL INTERFERING;

EID: 84898970169     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12145     Document Type: Review

References (106)

1. Virchow R,. Über den Gang der amyloiden degeneration. Virchows Arch, 1855; 8: 364-368.
2. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P,. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid, 2012; 19: 167-170.
3. Cohen AS, Calkins E,. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature, 1959; 183: 1202-1203.
4. Glenner GG,. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med, 1980; 302: 1283-1292.
5. Glenner GG,. Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med, 1980; 302: 1333-1343.
6. Sekijima Y, Kelly JW, Ikeda S,. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des, 2008; 14: 3219-3230.
7. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE,. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid, 2003; 10: 160-184.
8. Sekijima Y, Yoshida K, Tokuda T, Ikeda S,. Familial Transthyretin Amyloidosis (January 2012) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle. 1993-2012. Available at: http://www.genetests.org.
9. Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P, Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med, 1983; 75: 618-623.
10. Westermark P, Sletten K, Johansson B, Cornwell GG III,. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA, 1990; 87: 2843-2845.
11. Benson MD,. Amyloidosis. In:, Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases, 8th edn. vol 4. New York: McGraw-Hill, 5345-5378, 2001.
12. Holmgren G, Costa PM, Andersson C, et al,. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet, 1994; 31: 351-354.
13. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V,. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid, 2008; 15: 181-186.
14. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN,. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med, 1997; 336: 466-473.
15. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD, A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid, 2005; 12: 127-130.
16. Tanskanen M, Kiuru-Enari S, Tienari P, et al,. Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid, 2006; 13: 164-169.
17. Ueda M, Horibata Y, Shono M, et al,. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol, 2011; 24: 1533-1544.
18. Nakagawa M, Sekijima Y, Tojo K, Ikeda S,. High prevalence of ATTR amyloidosis in endomyocardial biopsy-proven cardiac amyloidosis patients. Amyloid, 2013; 20: 138-140.
19. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN,. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med, 1996; 101: 395-400.
20. Pitkanen P, Westermark P, Cornwell GG III,. Senile systemic amyloidosis. Am J Pathol, 1984; 117: 391-399.
21. Sekijima Y, Uchiyama S, Tojo K, et al,. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol, 2011; 42: 1785-1791.
22. Sueyoshi T, Ueda M, Jono H, et al,. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol, 2011; 42: 1259-1264.
23. Takanashi T, Matsuda M, Yazaki M, Yamazaki H, Nawata M, Katagiri Y, Ikeda S,. Synovial deposition of wild-type transthyretin-derived amyloid in knee joint osteoarthritis patients. Amyloid, 2013; 20: 151-155.
24. Takei Y, Hattori T, Gono T, Tokuda T, Saitoh S, Hoshii Y, Ikeda S,. Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Amyloid, 2002; 9: 252-255.
25. Takei Y, Hattori T, Tokuda T, Matsuda M, Saitoh S, Hoshii Y, Ikeda S,. Senile systemic amyloidosis starting as bilateral carpal and left ulnar tunnel syndrome. Intern Med, 2003; 42: 1050-1051.
26. Kodaira M, Sekijima Y, Tojo K, et al,. Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. J Peripher Nerv Syst, 2008; 13: 148-150.
27. Wallace MR, Naylor SL, Kluvebeckerman B, Long GL, McDonald L, Shows TB, Benson MD,. Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun, 1985; 129: 753-758.
28. Sasaki H, Yoshioka N, Takagi Y, Sakaki Y,. Structure of the chromosomal gene for human serum prealbumin. Gene, 1985; 37: 191-197.
29. Tsuzuki T, Mita S, Maeda S, Araki S, Shimada K,. Structure of the human prealbumin gene. J Biol Chem, 1985; 260: 2224-2227.
30. Blake CC, Geisow MJ, Swan IDA,. Structure of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol, 1974; 88: 1-12.
31. Felding P, Fex G,. Cellular origin of prealbumin in the rat. Biochim Biophys Acta, 1982; 716: 446-449.
32. Mita S, Maeda S, Shimada K, Araki S,. Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. J Biochem, 1986; 100: 1215-1222.
33. Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS,. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem, 1985; 260: 1793-1798.
34. Dickson PW, Aldred AR, Marley PD, Tu GF, Howlett GJ, Schreiber G,. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem Biophys Res Commun, 1985; 127: 890-895.
35. Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, Segal MB,. Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am J Physiol, 1990; 258: R338-R345.
36. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ,. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA, 1993; 90: 2375-2379.
37. Irace G, Edelhoch H,. Thyroxine-induced conformational changes in prealbumin. Biochemistry, 1978; 17: 5729-5733.
38. Hagen GA, Elliott WJ,. Transport of thyroid hormones in serum and cerebrospinal fluid. J Clin Endocrinol Metab, 1973; 37: 415-422.
39. Nilsson SF, Rask L, Peterson PA,. Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association. J Biol Chem, 1975; 250: 8554-8563.
40. Monaco HL, Rizzi M, Coda A,. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science, 1995; 268: 1039-1041.
41. Noy N, Slosberg E, Scarlata S,. Interactions of retinol with binding proteins: studies with retinol-binding protein and with transthyretin. Biochemistry, 1992; 31: 11118-11124.
42. Colon W, Kelly JW,. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry, 1992; 31: 8654-8660.
43. McCutchen SL, Colon W, Kelly JW,. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry, 1993; 32: 12119-12127.
44. McCutchen SL, Lai ZH, Miroy GJ, Kelly JW, Colon W,. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry, 1995; 34: 13527-13536.
45. Lai ZH, Colon W, Kelly JW,. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry, 1996; 35: 6470-6482.
46. Quintas A, Saraiva MJM, Brito RMM,. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett, 1997; 418: 297-300.
47. Quintas A, Saraiva MJM, Brito RMM,. The tetrameric protein transthyretin dissociates to a non-native monomer in solution-A novel model for amyloidogenesis. J Biol Chem, 1999; 274: 32943-32949.
48. Jiang X, Smith CS, Petrassi HM, Hammarstrom P, White JT, Sacchettini JC, Kelly JW,. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry, 2001; 40: 11442-11452.
49. Foss TR, Wiseman RL, Kelly JW,. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry, 2005; 44: 15525-15533.
50. Foss TR, Kelker MS, Wiseman RL, Wilson IA, Kelly JW,. Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis. J Mol Biol, 2005; 347: 841-854.
51. Sekijima Y, Tokuda T, Kametani F, Tanaka K, Maruyama K, Ikeda S,. Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid, 2001; 8: 257-262.
52. Schneider F, Hammarstrom P, Kelly JW,. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci, 2001; 10: 1606-1613.
53. Naiki H, Gejyo F,. Kinetic analysis of amyloid fibril formation. Methods Enzymol, 1999; 309: 305-318.
54. Hurshman AR, White JT, Powers ET, Kelly JW,. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry, 2004; 43: 7365-7381.
55. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW,. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA, 2002; 99: 16427-16432.
56. Sekijima Y, Hammarstrom P, Matsumura M, et al,. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest, 2003; 83: 409-417.
57. Hammarstrom P, Sekijima Y, White JT, et al,. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry, 2003; 42: 6656-6663.
58. Sekijima Y, Wiseman RL, Matteson J, et al,. The biological and chemical basis for tissue-selective amyloid disease. Cell, 2005; 121: 73-85.
59. Ferrao-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel H, Kelly JW, Foguel D,. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. J Mol Biol, 2003; 328: 963-974.
60. Hurshman Babbes AR, Powers ET, Kelly JW,. Quantification of the thermodynamically linked quaternary and tertiary stabilities of transthyretin and it's disease-associated variants. Biochemistry, 2008; 47: 6969-6984.
61. Hammarstrom P, Schneider F, Kelly JW,. Trans-suppression of misfolding in an amyloid disease. Science, 2001; 293: 2459-2462.
62. Sekijima Y, Dendle MT, Wiseman RL, White JT, D'Haeze W, Kelly JW,. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. Amyloid, 2006; 13: 57-66.
63. Tojo K, Sekijima Y, Kelly JW, Ikeda SI,. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res, 2006; 56: 441-449.
64. White JT, Kelly JW,. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci USA, 2001; 98: 13019-13024.
65. Sato T, Susuki S, Suico MA, et al,. Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J, 2007; 26: 2501-2512.
66. Holmgren G, Ericzon BG, Groth CG, et al,. Clinical improvement and amyloid regression after liver-transplantation in hereditary transthyretin amyloidosis. Lancet, 1993; 341: 1113-1116.
67. Suhr OB, Holmgren G, Steen L, et al,. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation, 1995; 60: 933-938.
68. Herlenius G, Wilczek HE, Larsson M, Ericzon BG,; Familial Amyloidotic P. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation, 2004; 77: 64-71.
69. Ikeda S, Takei Y, Yanagisawa N, Matsunami H, Hashikura Y, Ikegami T, Kawasaki S,. Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. Ann Intern Med, 1997; 127: 618-620.
70. Takei Y, Ikeda S, Hashikura Y, Ikegami T, Kawasaki S,. Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. Ann Intern Med, 1999; 131: 592-595.
71. Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S,. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl, 2008; 14: 563-570.
72. Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda S,. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol, 2008; 255: 1220-1225.
73. Holmgren G, Steen L, Ekstedt J, et al,. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet, 1991; 40: 242-246.
74. Ando Y, Tanaka Y, Nakazato M, et al,. Change in the age of onset in patients with familial amyloidotic polyneuropathy type I. Biochem Biophys Res Commun, 1995; 211: 354-358.
75. Adams D, Samuel D, Goulon-Goeau C, et al,. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain, 2000; 123 (Pt 7): 1495-1504.
76. Yamamoto S, Wilczek HE, Nowak G, et al,. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant, 2007; 7: 2597-2604.
77. Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda SI,. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol, 2008; 255: 1220-1225.
78. Wilczek HE, Larsson M, Ericzon BG,. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid, 2011; 18 (Suppl 1): 193-195.
79. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH,. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation, 1997; 64: 74-80.
80. Stangou AJ, Hawkins PN, Heaton ND, et al,. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation, 1998; 66: 229-233.
81. Yamashita T, Ando Y, Okamoto S, et al,. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology, 2012; 78: 637-643.
82. Yazaki M, Tokuda T, Nakamura A, et al,. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun, 2000; 274: 702-706.
83. Ando Y, Terazaki H, Nakamura M, et al,. A different amyloid formation mechanism: De novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation, 2004; 77: 345-349.
84. Sousa MM, Ferrao J, Fernandes R, et al,. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest, 2004; 84: 865-873.
85. Stangou AJ, Heaton ND, Hawkins PN,. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med, 2005; 352: 2356.
86. Takei Y, Gono T, Yazaki M, et al,. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl, 2007; 13: 215-218.
87. Goto T, Yamashita T, Ueda M, et al,. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant, 2006; 6: 2512-2515.
88. Miroy GJ, Lai ZH, Lashuel HA, Peterson SA, Strang C, Kelly JW,. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA, 1996; 93: 15051-15056.
89. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW,. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science, 2003; 299: 713-716.
90. Miller SR, Sekijima Y, Kelly JW,. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest, 2004; 84: 545-552.
91. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW,. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res, 2005; 38: 911-921.
92. Wiseman RL, Green NS, Kelly JW,. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry, 2005; 44: 9265-9274.
93. Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW,. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc, 2005; 127: 5540-5551.
94. Sekijima Y, Dendle MA, Kelly JW,. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid, 2006; 13: 236-249.
95. Berk JL, Suhr OB, Obici L, et al,. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA, 2013; 310: 2658-2667.
96. Bulawa CE, Connelly S, Devit M, et al,. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA, 2012; 109: 9629-9634.
97. de Lartigue J,. Tafamidis for transthyretin amyloidosis. Drugs Today (Barc), 2012; 48: 331-337.
98. Coelho T, Maia LF, Martins da Silva A, et al,. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology, 2012; 79: 785-792.
99. Propsting MJ, Blaschke M, Haas RE, Genschel J, Hedrich HJ, Manns MP, Schmidt HHJ,. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem Biophys Res Commun, 1999; 260: 313-317.
100. Tanaka K, Yamada T, Ohyagi Y, Asahara H, Horiuchi I, Kira J,. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci, 2001; 183: 79-84.
101. Kurosawa T, Igarashi S, Nishizawa M, Onodera O,. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun, 2005; 337: 1012-1018.
102. Coelho T, Adams D, Silva A, et al,. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med, 2013; 369: 819-829.
103. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW,. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve, 2006; 33: 609-618.
104. Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW, Monia BP,. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid, 2010; 17: 43-49.
105. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP,. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid, 2012; 19 (Suppl 1): 43-44.
106. Nakamura M, Ando Y, Nagahara S, et al,. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther, 2004; 11: 838-846.